Company Announcement No 08, 2019
Solid sales growth and profitability in Q3, but reduced organic growth outlook for the year.
© 2019 GlobeNewswire, Inc. All Rights Reserved.
OPKO Health (Nasdaq: OPK) and Pfizer (NYSE: PFE) Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
**Disclaimer: Crown Equity Holdings Inc. has received $5,000.00 (five thousand dollars) in cash from Nass Valley Gateway Ltd. (CSE:NVG) (FSE:3NVN) for 30 days of advertisement services